Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ETV6 - NTRK3||Advanced Solid Tumor||sensitive||Altiratinib||Preclinical||Actionable||In a preclinical study, transformed cells expressing ETV6-NTRK3 demonstrated sensitivity to Altiratinib (DCC-2701) in culture, resulting in inhibition of Ntrk3 phosphorylation and decreased cell proliferation (AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 790).||detail...|
|PubMed Id||Reference Title||Details|
|Abstract 790: Altiratinib is a potent inhibitor of TRK kinases and is efficacious in TRK-fusion driven cancer models||Full reference...|